[Form 4] Maze Therapeutics, Inc. Insider Trading Activity
Maze Therapeutics director Charles J. Homcy was granted a stock option to buy 18,000 shares of Maze Therapeutics common stock at an exercise price of $23.67 per share. The option is reported as a direct holding and covers 18,000 underlying shares with an exercise/expiration reference shown as 09/21/2035. The option vests monthly as to 1/9 of the award, with the first tranche vesting on October 1, 2025, subject to the holder’s continued service.
The grant increases the reporting person’s beneficial ownership by 18,000 shares on the reported transaction date of September 22, 2025. No cash exercise is indicated in the filing and the option is described as a right to buy common stock under standard vesting conditions tied to continued service.
Il direttore di Maze Therapeutics Charles J. Homcy ha ricevuto un'opzione su azioni per acquistare 18.000 azioni di Maze Therapeutics azioni ordinarie a un prezzo di esercizio di $23,67 per azione. L'opzione è riportata come possesso diretto e copre 18.000 azioni sottostanti con un riferimento di esercizio/scadenza indicato come 21/09/2035. L'opzione vesta mensilmente per 1/9 dell'assegnazione, con la prima tranche che matura il 1 ottobre 2025, soggetta al proseguimento della collaborazione da parte del titolare.
Il grant aumenta la proprietà beneficiaria della persona segnalante di 18.000 azioni nella data di transazione riportata del 22 settembre 2025. Non è indicato alcun esercizio in contanti nel fascicolo e l'opzione è descritta come diritto di acquistare azioni ordinarie soggetto alle condizioni di vesting standard legate al proseguimento della collaborazione.
El director de Maze Therapeutics, Charles J. Homcy, recibió una opción de compra de 18,000 acciones de Maze Therapeutics acciones comunes a un precio de ejercicio de $23.67 por acción. La opción se reporta como tenencia directa y cubre 18,000 acciones subyacentes con una referencia de ejercicio/vencimiento que aparece como 21/09/2035. La opción se consolida mensualmente en 1/9 de la adjudicación, siendo la primera tramo que vence el 1 de octubre de 2025, sujeta al continuo servicio del titular.
La concesión aumenta la propiedad beneficiosa de la persona reportante en 18,000 acciones en la fecha de transacción reportada del 22/09/2025. No se indica ejercicio en efectivo en el archivo y la opción se describe como un derecho a comprar acciones comunes bajo condiciones de vesting estándar ligadas al servicio continuo.
Maze Therapeutics 이사 Charles J. Homcy는 Maze Therapeutics 일반 주식 18,000주를 매수할 수 있는 주식매수선택권을 부여받았으며 행사가격은 주당 $23.67이다. 이 옵션은 직접 보유로 보고되며 행사/만료 참고로 09/21/2035가 표시된 18,000주 underlying 주식을 커버한다. 옵션은 매월 상여의 1/9에 해당하여 첫 분할은 2025년 10월 1일에 비구속 조건 하에 부여자의 계속된 근무에 따라 성립한다.
그 수여로 보고 대상자의 유익 소유가 보고된 거래일인 2025년 9월 22일에 18,000주 증가한다. filing에는 현금 행사로 표시되지 않으며 옵션은 지속적인 서비스에 묶인 표준 vesting 조건 하에 보통주를 살 수 있는 권리로 설명된다.
Le directeur de Maze Therapeutics, Charles J. Homcy a reçu une option d’achat sur 18 000 actions ordinaires de Maze Therapeutics à un prix d’exercice de $23,67 par action. L’option est déclarée comme une détention directe et couvre 18 000 actions sous-jacentes avec une référence d’exercice/d’échéance indiquée comme 21/09/2035. L’option vesture mensuellement à raison de 1/9 de la prime, la première tranche devenant acquise le 1er octobre 2025, sous réserve de la poursuite des services par le titulaire.
La attribution augmente la propriété bénéficiaire de la personne déclarante de 18 000 actions à la date de transaction déclarée du 22/09/2025. Aucun exercice en espèces n’est indiqué dans le dossier et l’option est décrite comme un droit d’acheter des actions ordinaires sous des conditions de vesting standard liées à la poursuite du service.
Maze Therapeutics-Direktor Charles J. Homcy erhielt eine Aktienoption zum Kauf von 18.000 Stammaktien von Maze Therapeutics zu einem Ausübungspreis von $23,67 pro Aktie. Die Option wird als direkte Beteiligung gemeldet und deckt 18.000 zugrunde liegende Aktien mit einer Ausübungs-/Laufzeitreferenz 09/21/2035 ab. Die Option vestet monatlich mit 1/9 der Zuwendung, wobei der erste Tranche am 1. Oktober 2025 vestet, vorbehaltlich der fortgesetzten Tätigkeit des Inhabers.
Die Gewährung erhöht das wirtschaftliche Eigentum der meldenden Person um 18.000 Aktien zum angegebenen Transaktionsdatum 22.09.2025. In der Einreichung ist kein Barausübung angegeben, und die Option wird als Recht zum Kauf von Stammaktien unter Standard-Vesting-Bedingungen beschrieben, die an die fortgesetzte Dienstausübung gebunden sind.
مدير Maze Therapeutics تشارلز ج. هومسي مُنِح خيار أسهم لشراء 18,000 سهمًا من أسهم Maze Therapeutics العادية بسعر تنفيذ $23.67 للسهم. يُبلّغ عن الخيار كحيازة مباشرة ويغطي 18,000 سهمًا أساسيًا مع إشارة تنفيذ/انتهاء مبيّنة كـ 21/09/2035. يتم تقويم الخيار شهريًا بنسبة 1/9 من الجائزة، مع استحقاق الدفعة الأولى في 1 أكتوبر 2025، رهناً باستمرار خدمة الحائز.
تزيد المنحة الملكية المفيدة للشخص المبلَّغ عنها بمقدار 18,000 سهم في تاريخ المعاملة المبلَّغ عنه بتاريخ 22/09/2025. لا يُشير الملف إلى ممارسة نقدية ويُوصف الخيار بأنه حق في شراء أسهم عادية وفق شروط الاستحقاق القياسية المرتبطة بالخدمة المستمرة.
Maze Therapeutics 董事 Charles J. Homcy 获得了一项股票期权，购买 Maze Therapeutics 普通股 18,000 股，行使价格为每股 $23.67。该期权被报告为直接持有，覆盖 18,000 股基础股票，行使/到期参照为 09/21/2035。该期权按月归属，归属于 奖项的1/9，第一批将于 2025年10月1日 授予，前提是持有人持续任职。
本次授予在报告的交易日期 2025年9月22日 将报告人对受益所有权增加 18,000 股。 filing 未指明现金行使，该期权被描述为在持续任职条件下购买普通股的权利。
- Director alignment: Award vests over time, aligning the director with shareholder interests through service-based vesting
- Direct ownership disclosed: The option is recorded as a direct holding for 18,000 shares, providing transparency
- Potential dilution: Grant of 18,000-option shares could dilute existing shareholders when exercised if not managed
- Limited context: Filing does not disclose total outstanding options or aggregate insider holdings to assess materiality
Insights
TL;DR: A director received a standard service-vested option for 18,000 shares at $23.67, modestly increasing insider-held potential equity.
The option grant of 18,000 shares at a $23.67 strike appears to be a routine director compensation award rather than a transaction to monetize holdings. Vesting is back-loaded over nine monthly tranches after October 1, 2025, which aligns incentives with continued service. The direct ownership entry indicates the reporting person holds economic exposure to the underlying shares once vested. This is a single, non-derivative-linked director grant and does not disclose any concurrent exercise or sale activity.
TL;DR: Governance-wise this is a standard service-based option grant for a director; materiality to shareholders is limited absent larger compensation context.
The filing documents a freshly granted stock option with time-based vesting that ties the director’s pay to future company performance and tenure. From a governance perspective, such awards are common to align director interests with shareholders. The filing does not disclose accelerated vesting, special performance conditions, or transfer to related parties. Without additional information on total outstanding options or director compensation policies, the grant appears routine and not a material corporate governance event.
Il direttore di Maze Therapeutics Charles J. Homcy ha ricevuto un'opzione su azioni per acquistare 18.000 azioni di Maze Therapeutics azioni ordinarie a un prezzo di esercizio di $23,67 per azione. L'opzione è riportata come possesso diretto e copre 18.000 azioni sottostanti con un riferimento di esercizio/scadenza indicato come 21/09/2035. L'opzione vesta mensilmente per 1/9 dell'assegnazione, con la prima tranche che matura il 1 ottobre 2025, soggetta al proseguimento della collaborazione da parte del titolare.
Il grant aumenta la proprietà beneficiaria della persona segnalante di 18.000 azioni nella data di transazione riportata del 22 settembre 2025. Non è indicato alcun esercizio in contanti nel fascicolo e l'opzione è descritta come diritto di acquistare azioni ordinarie soggetto alle condizioni di vesting standard legate al proseguimento della collaborazione.
El director de Maze Therapeutics, Charles J. Homcy, recibió una opción de compra de 18,000 acciones de Maze Therapeutics acciones comunes a un precio de ejercicio de $23.67 por acción. La opción se reporta como tenencia directa y cubre 18,000 acciones subyacentes con una referencia de ejercicio/vencimiento que aparece como 21/09/2035. La opción se consolida mensualmente en 1/9 de la adjudicación, siendo la primera tramo que vence el 1 de octubre de 2025, sujeta al continuo servicio del titular.
La concesión aumenta la propiedad beneficiosa de la persona reportante en 18,000 acciones en la fecha de transacción reportada del 22/09/2025. No se indica ejercicio en efectivo en el archivo y la opción se describe como un derecho a comprar acciones comunes bajo condiciones de vesting estándar ligadas al servicio continuo.
Maze Therapeutics 이사 Charles J. Homcy는 Maze Therapeutics 일반 주식 18,000주를 매수할 수 있는 주식매수선택권을 부여받았으며 행사가격은 주당 $23.67이다. 이 옵션은 직접 보유로 보고되며 행사/만료 참고로 09/21/2035가 표시된 18,000주 underlying 주식을 커버한다. 옵션은 매월 상여의 1/9에 해당하여 첫 분할은 2025년 10월 1일에 비구속 조건 하에 부여자의 계속된 근무에 따라 성립한다.
그 수여로 보고 대상자의 유익 소유가 보고된 거래일인 2025년 9월 22일에 18,000주 증가한다. filing에는 현금 행사로 표시되지 않으며 옵션은 지속적인 서비스에 묶인 표준 vesting 조건 하에 보통주를 살 수 있는 권리로 설명된다.
Le directeur de Maze Therapeutics, Charles J. Homcy a reçu une option d’achat sur 18 000 actions ordinaires de Maze Therapeutics à un prix d’exercice de $23,67 par action. L’option est déclarée comme une détention directe et couvre 18 000 actions sous-jacentes avec une référence d’exercice/d’échéance indiquée comme 21/09/2035. L’option vesture mensuellement à raison de 1/9 de la prime, la première tranche devenant acquise le 1er octobre 2025, sous réserve de la poursuite des services par le titulaire.
La attribution augmente la propriété bénéficiaire de la personne déclarante de 18 000 actions à la date de transaction déclarée du 22/09/2025. Aucun exercice en espèces n’est indiqué dans le dossier et l’option est décrite comme un droit d’acheter des actions ordinaires sous des conditions de vesting standard liées à la poursuite du service.
Maze Therapeutics-Direktor Charles J. Homcy erhielt eine Aktienoption zum Kauf von 18.000 Stammaktien von Maze Therapeutics zu einem Ausübungspreis von $23,67 pro Aktie. Die Option wird als direkte Beteiligung gemeldet und deckt 18.000 zugrunde liegende Aktien mit einer Ausübungs-/Laufzeitreferenz 09/21/2035 ab. Die Option vestet monatlich mit 1/9 der Zuwendung, wobei der erste Tranche am 1. Oktober 2025 vestet, vorbehaltlich der fortgesetzten Tätigkeit des Inhabers.
Die Gewährung erhöht das wirtschaftliche Eigentum der meldenden Person um 18.000 Aktien zum angegebenen Transaktionsdatum 22.09.2025. In der Einreichung ist kein Barausübung angegeben, und die Option wird als Recht zum Kauf von Stammaktien unter Standard-Vesting-Bedingungen beschrieben, die an die fortgesetzte Dienstausübung gebunden sind.
FAQ
What did Maze Therapeutics (MAZE) disclose about insider activity?
When does the option vest and become exercisable?
How many shares will the reporting person beneficially own after the reported transaction?
What is the term or expiration referenced for the option?
Was any cash exercise or sale reported alongside the grant?
